Form 13-F position report

TRILLIUM THERAPEUTICS INC

Reported by Tekla Capital Management LLC

CUSIP 89620X506 Manager CIK 0001300336

Reported 0 shares, down 529,226 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q3 2021
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 18 Through Q3 2021

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2018-09-30 2717000
2018-12-31 763000
2019-03-31 294000
2019-06-30 146000
2019-09-30 137000
2019-12-31 459000
2020-03-31 1810000
2020-06-30 3625000
2020-09-30 6367000
2020-12-31 12030000
2021-03-31 5684000
2021-06-30 5133000
2021-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

13 quarters
Quarterly reported position history for TRILLIUM THERAPEUTICS INC held by Tekla Capital Management LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2021 Reduced 0 -529,226 (-100.0%) 0 $0 2021-11-12
Q2 2021 Unchanged 529,226 0 (0.0%) 0.17% $5,133,000 2021-08-13
Q1 2021 Reduced 529,226 -288,558 (-35.3%) 0.2% $5,684,000 2021-05-14
Q4 2020 Added 817,784 +369,735 (82.5%) 0.42% $12,030,000 2021-02-12
Q3 2020 Unchanged 448,049 0 (0.0%) 0.24% $6,367,000 2020-11-13
Q2 2020 Unchanged 448,049 0 (0.0%) 0.14% $3,625,000 2020-08-13
Q1 2020 Added 448,049 +1,950 (0.4%) 0.08% $1,810,000 2020-05-14
Q4 2019 Unchanged 446,099 0 (0.0%) 0.02% $459,000 2020-02-13
Q3 2019 Unchanged 446,099 0 (0.0%) < 0.01% $137,000 2019-11-13
Q2 2019 Unchanged 446,099 0 (0.0%) < 0.01% $146,000 2019-08-14
Q1 2019 Unchanged 446,099 0 (0.0%) 0.01% $294,000 2019-05-14
Q4 2018 Reduced 446,099 -22,300 (-4.8%) 0.03% $763,000 2019-02-13
Q3 2018 Unchanged 468,399 0 (0.0%) 0.1% $2,717,000 2018-11-13
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

215 managers reported TRILLIUM THERAPEUTICS INC for Q3 2021.

Managers reporting TRILLIUM THERAPEUTICS INC in Q3 2021.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 6,112,610 +498,305 < 0.01% $107,337,000 2 qtrs
NEA Management Company LLC Unchanged 5,736,363 0 1.2% $100,731,000 18 qtrs
Avoro Capital Advisors LLC Unchanged 5,700,000 0 1.57% $100,092,000 7 qtrs
EVENTIDE ASSET MANAGEMENT LLC Reduced 5,227,376 -4,282,624 1.21% $91,793,000 6 qtrs
Magnetar Financial LLC New 3,271,390 +3,271,390 0.59% $57,446,000 1 qtr
Pentwater Capital Management LP New 3,140,000 +3,140,000 0.56% $55,138,000 1 qtr
Versor Investments LP New 1,923,455 +1,923,455 1.04% $33,776,000 1 qtr
GABELLI FUNDS LLC Added 1,793,880 +1,481,780 0.21% $31,501,000 4 qtrs
Westchester Capital Management LLC New 1,597,153 +1,597,153 0.81% $28,046,000 1 qtr
JPMorgan Chase & Co Added 1,510,226 +1,472,671 < 0.01% $26,519,000 2 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2021
Filed
November 12, 2021
Filing type
13F-HR
Position type
Common

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.